Personalis (PSNL) News Mentions Statistics 2025

10%

1W 0%

Est. daily news mentions.

Similar companies

Company		News Mentions
	Amgen AMGN	0 100%
	Gilead Sciences GILD	1 0%
	Catalyst Pharmaceuticals CPRX	0 100%
	Inovio Pharmaceuticals INO	1 0%
	Anavex Life Sciences AVXL	0 0%

The 16% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 159%

December 25

Researchers find ctDNA test predicts lung cancer outcomes in study

January 13

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

January 13

Elevai Labs Enters Asset Purchase Agreement with PMGC Holdings Inc.

January 9

Global and US Companion Diagnostic Market Research 2025: Exploring the Companion Diagnostics Revolution and Forging New Markets and Diagnostic-Therapeutic Partnerships

January 7

Why Moderna Inc. (MRNA) Is Skyrocketing

January 2

How often is Personalis mentioned in the news?

Personalis was mentioned an estimated 1 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Personalis performing compared to its industry peers?

Personalis underperforms its industry peers when it comes to News Mentions, ranking in the 14th percentile.

Why is it important to track news mentions for Personalis?

By monitoring mentions in the news for Personalis, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Personalis, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

Top Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact

Personalis (PSNL) - News Mentions

Similar companies

Amgen

Gilead Sciences

Catalyst Pharmaceuticals

Inovio Pharmaceuticals

Anavex Life Sciences

Personalis’ (PSNL) Buy Rating Reiterated at HC Wainwright

Personalis’ (PSNL) “Buy” Rating Reiterated at Needham & Company LLC

Personalis (NASDAQ:PSNL) Price Target Raised to $9.00

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Barclays PLC Boosts Holdings in Personalis, Inc. (NASDAQ:PSNL)

Personalis, Inc. (NASDAQ:PSNL) Stock Holdings Lowered by Stifel Financial Corp

Personalis, Inc. Amends Sales Agreement with Piper Sandler & Co. and BTIG

Reviewing Grail (NASDAQ:GRAL) and Personalis (NASDAQ:PSNL)